Sulfated fibroin, a novel sulfated peptide derived from silk, inhibits human immunodeficiency virus replication in vitro

被引:48
作者
Gotoh, K
Izumi, H
Kanamoto, T
Tamada, Y
Nakashima, H
机构
[1] Kagoshima Univ, Dept Microbiol & Immunol, Sch Dent, Kagoshima 8908544, Japan
[2] Shin Nippon Biomed Labs, Kagoshima 8911394, Japan
[3] Natl Inst Sericultural & Entomol Sci, Biomimet Lab, Tsukuba, Ibaraki 3058634, Japan
关键词
AIDS; silk fibroin; sulfated peptides; binding inhibitor; anti-HIV formulation;
D O I
10.1271/bbb.64.1664
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We prepared two kinds of sulfated silk fibroins, SclFib30 and SclFib31, which contain different amounts of sulfate. These sulfated silk fibroins have anti-HIV-l activity in vitro, apparently due to interference with the adsorption of virus particles to CD4(+) cells, and completely blocked virus binding to the cells at a concentration of 100 mu g/ml. Sulfated fibroins also abolished cell-to-cell infection-induced syncytium formation upon cocultivation of MOLT-4 and MOLT-4/HIV-1(IIIB) cells, suggesting that they would interfere with gp120 and prevent the formation of gp120/CD4 complex. Silk is used in biomaterials such as surgical sutures and is believed to be a safe material for humans. In accordance with low anticoagulant activity and high anti-HIV-1 activity against both X4 HIV-1 and R5 HIV-1 strains, sulfated silk fibroins have potential as antiviral material such for a vaginal anti-HIV formulation.
引用
收藏
页码:1664 / 1670
页数:7
相关论文
共 37 条
[1]   ORAL DEXTRAN SULFATE (UA001) IN THE TREATMENT OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND AIDS-RELATED COMPLEX [J].
ABRAMS, DI ;
KUNO, S ;
WONG, R ;
JEFFORDS, K ;
NASH, M ;
MOLAGHAN, JB ;
GORTER, R ;
UENO, R .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (03) :183-188
[2]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[3]   T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure [J].
Arakaki, R ;
Tamamura, H ;
Premanathan, M ;
Kanbara, K ;
Ramanan, S ;
Mochizuki, K ;
Baba, M ;
Fujii, N ;
Nakashima, H .
JOURNAL OF VIROLOGY, 1999, 73 (02) :1719-1723
[4]   A new classification for HIV-1 [J].
Berger, EA ;
Doms, RW ;
Fenyö, EM ;
Korber, BTM ;
Littman, DR ;
Moore, JP ;
Sattentau, QJ ;
Schuitemaker, H ;
Sodroski, J ;
Weiss, RA .
NATURE, 1998, 391 (6664) :240-240
[5]  
Berger EA, 1997, AIDS, V11, pS3
[6]   Chemokines and HIV-1 second receptors: The therapeutic connection [J].
Cairns, JS ;
D'Souza, MP .
NATURE MEDICINE, 1998, 4 (05) :563-568
[7]   Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection [J].
Chackerian, B ;
Long, EM ;
Luciw, PA ;
Overbaugh, J .
JOURNAL OF VIROLOGY, 1997, 71 (05) :3932-3939
[8]   The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates [J].
Choe, H ;
Farzan, M ;
Sun, Y ;
Sullivan, N ;
Rollins, B ;
Ponath, PD ;
Wu, LJ ;
Mackay, CR ;
LaRosa, G ;
Newman, W ;
Gerard, N ;
Gerard, C ;
Sodroski, J .
CELL, 1996, 85 (07) :1135-1148
[9]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[10]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628